MimiVax's glioblastoma vaccine misses primary endpoint in ph. 2
MimiVax's glioblastoma vaccine missed its primary endpoint in a Phase 2 trial.
MimiVax
Private
Clinical-stage immunotherapy company developing SurVaxM, a survivin-targeting cancer vaccine, for glioblastoma and other cancers.
Company Info
Sector:Immunotherapy / Oncology
Headquarters:Buffalo, New York, United States
Founded:2012
Website:www.mimivax.com/